Can a patient with alanine aminotransferase 104 U/L, aspartate aminotransferase 54 U/L, and triglycerides 305 mg/dL safely receive Ilumya (tildrakizumab)?

Can This Patient Receive Ilumya?

Yes, this patient can receive Ilumya (tildrakizumab) - the elevated liver enzymes and triglycerides are not contraindications to treatment. The FDA prescribing information for Ilumya does not list hepatic impairment or elevated transaminases as contraindications, and there are no specific liver enzyme or triglyceride thresholds that preclude initiation 1.

Key Clinical Considerations

Liver Enzyme Elevations

The patient's ALT of 104 U/L and AST of 54 U/L represent mild elevations (approximately 2-3 times the upper limit of normal for ALT, assuming normal range ~40 U/L). According to multiple guidelines addressing hepatotoxicity monitoring:

• The threshold for clinical concern is ALT/AST >3 times the upper limit of normal 2, 3, 4, 3
• This patient falls below this threshold
• Ilumya's prescribing information does not require baseline liver function testing or list hepatic dysfunction as a contraindication 1

Triglyceride Level

The triglyceride level of 305 mg/dL is elevated but not severely so:

• Severe hypertriglyceridemia requiring urgent intervention is defined as ≥500 mg/dL due to pancreatitis risk 5, 6
• This patient's level of 305 mg/dL falls in the moderate range (200-499 mg/dL)
• Ilumya does not have triglyceride-related contraindications 1

Actual Contraindications to Ilumya

The only absolute contraindication is previous serious hypersensitivity reaction to tildrakizumab or excipients 1. The primary safety concerns are:

• Active clinically important infections
• Tuberculosis (requires screening before initiation)
• History of recurrent infections (requires risk-benefit assessment)

Recommended Management Approach

Before Starting Ilumya:

1. Investigate the cause of elevated transaminases - rule out viral hepatitis, alcohol use, medication effects, or non-alcoholic fatty liver disease
2. Address the hypertriglyceridemia through lifestyle modifications (dietary fat reduction, alcohol cessation, weight management, physical activity) 5, 6
3. Screen for tuberculosis as required 1
4. Update age-appropriate immunizations 1

Monitoring During Treatment:

• Liver enzymes should be monitored if signs/symptoms of hepatotoxicity develop 3
• Routine monitoring of transaminases is not required for Ilumya specifically
• Monitor triglycerides every 3-6 months and consider lipid-lowering therapy if levels remain >200 mg/dL despite lifestyle changes 5, 7
• Consider statin therapy if cardiovascular risk factors are present, as the patient likely has metabolic syndrome given the combined findings 3, 4

Important Caveats

If transaminases rise to >3 times the upper limit of normal during treatment, thoroughly evaluate for non-drug causes including viral hepatitis, alcohol use, and other hepatotoxic medications 3. However, this threshold has not been reached at baseline.

The combination of elevated liver enzymes and triglycerides suggests possible metabolic syndrome or non-alcoholic fatty liver disease 8, 9, 10. This underlying condition should be addressed concurrently but does not preclude biologic therapy - in fact, statins are not contraindicated in chronic stable liver disease and may provide benefit 3.